Detalhe da pesquisa
1.
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Mol Pharmacol
; 96(4): 419-429, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31467029
2.
Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.
Chem Biol Drug Des
; 96(2): 773-784, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32237047
3.
Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Oncotarget
; 11(25): 2462-2463, 2020 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32637035
4.
Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy.
ACS Chem Biol
; 13(5): 1148-1152, 2018 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29608269
5.
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Oncotarget
; 9(4): 5216-5232, 2018 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435174
6.
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).
Chem Commun (Camb)
; 53(54): 7577-7580, 2017 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636052